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Kaposi's sarcoma-associated herpesvirus (KSHV) is linked
to three different human cancers: Kaposi's sarcoma (KS),
primary effusion lymphoma (PEL) and multicentric Cas-
tleman's disease (MCD). We have previously reported that
the PI3K/Akt/mTOR pathway is critical for the survival of
KSHV-infected endothelial cells and B cells, and have
demonstrated that Rapamycin/Sirolimus, an inhibitor of
mTOR, can induce PEL cell death in vitro and in vivo (Sin
et al., Blood. 2007. 109(5):2165–73). We have now
extended these findings and demonstrate that therapeutic
targeting of other members of the PI3K/Akt/mTOR signal
transduction pathway can also induce cell death in PEL in
vitro and inhibit tumor growth in murine xenograft mod-
els. Importantly, some of these novel drug candidates
have passed clinical trials for other indications and can
therefore be tested for efficacy against KS and AIDS-asso-
ciated lymphomas.
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